FDA Panel Will Review Acorn’s CorCap Heart Failure Device June 22
This article was originally published in The Gray Sheet
Executive Summary
Acorn Cardiovascular will present data from 300 patients when it appears before FDA's Circulatory System Devices Panel for review of the CorCap ventricular support device June 22
You may also be interested in...
Acorn Releases CorCap Pivotal Trial Results, Anticipates 2005 Panel Review
Acorn Cardiovascular is planning a 2005 continued access protocol for its CorCap cardiac support device, which the company would like to see incorporated into an FDA-mandated post-market study
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.